Mason Lauren, Crosson Jason N, Mason John O, McGwin Gerald
Retina Consultants of Alabama, University of Alabama at Birmingham School of Medicine, Callahan Eye Hospital, 700 18th St. South, Suite 707, Birmingham, AL 35233, USA.
J Ophthalmol. 2017;2017:7398470. doi: 10.1155/2017/7398470. Epub 2017 Apr 4.
. To identify treatment preferences of patients with diabetic macular edema (DME) having undergone laser and intravitreal injections. . Patients with DME who received lasers and injections were surveyed, measuring preferences toward specific treatments. 66/210 diabetic patients met the criteria for our survey assessing preference for lasers and/or injections, incorporating demographics and treatment preference questions. Outcome measures included treatment preference (laser or injections), how often patients are willing to be treated, and how much vision they will sacrifice to avoid being treated every month. . 66 patients completed the survey. The mean diabetes duration was 20.7 years, the mean retina follow-up was 4.4 years, and patients received a mean of 4.82 lasers and 4.86 injections. 56% preferred injections, 33% preferred laser, and 11% had no preference. Regarding treatment effectiveness, 38% found no difference, 36% chose laser, and 25% chose injections. Regarding anxiety, 56% reported injection anxiety. While 50% versus 38% reported that laser was easier than injections. 91% would give up zero lines on the eye chart, and 76% would come in 12 times yearly for treatment to maintain vision. . Patients with DME have no profound preference regarding laser versus intravitreal injections but prefer aggressive treatment and are unwilling to sacrifice vision for less visits.
识别接受过激光治疗和玻璃体注射的糖尿病性黄斑水肿(DME)患者的治疗偏好。对接受过激光治疗和注射的DME患者进行调查,测量他们对特定治疗的偏好。210名糖尿病患者中有66名符合我们评估对激光治疗和/或注射治疗偏好的调查标准,调查内容包括人口统计学和治疗偏好问题。结果指标包括治疗偏好(激光治疗或注射治疗)、患者愿意接受治疗的频率,以及他们为了避免每月接受治疗而愿意牺牲多少视力。66名患者完成了调查。糖尿病平均病程为20.7年,视网膜平均随访时间为4.4年,患者平均接受了4.82次激光治疗和4.86次注射治疗。56%的患者更喜欢注射治疗,33%的患者更喜欢激光治疗,11%的患者无偏好。关于治疗效果,38%的患者认为没有差异,36%的患者选择激光治疗,25%的患者选择注射治疗。关于焦虑,56%的患者报告有注射焦虑。而50%的患者与38%的患者报告称激光治疗比注射治疗更容易。91%的患者愿意在视力表上放弃零行视力,76%的患者愿意每年接受12次治疗以维持视力。DME患者对于激光治疗和玻璃体注射治疗没有明显偏好,但更喜欢积极治疗,并且不愿意为了减少就诊次数而牺牲视力。